Joseph Bertino
About
In The Last Decade
Joseph Bertino
208 papers receiving 5.7k citations
Peers
Comparison fields: 5 of 138
- Pharmacology 1.7k
- Pharmacology 1.4k
- Oncology 1.3k
- Epidemiology 1.2k
- Molecular Biology 791
Countries citing papers authored by Joseph Bertino
This map shows the geographic impact of Joseph Bertino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Bertino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Bertino more than expected).
Fields of papers citing papers by Joseph Bertino
This network shows the impact of papers produced by Joseph Bertino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Bertino. The network helps show where Joseph Bertino may publish in the future.
Co-authorship network of co-authors of Joseph Bertino
This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Bertino. A scholar is included among the top collaborators of Joseph Bertino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Bertino. Joseph Bertino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 33 | |
| 2 | 49 | |
| 3 | 20 | |
| 4 | Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics | 2 |
| 5 | 16 | |
| 6 | 152 | |
| 7 | Dihydrofolate reductase as an oncogene: a microRNA binding site SNP leads to cellular transformation and drug resistance | 2 |
| 8 | 1 | |
| 9 | 55 | |
| 10 | 39 | |
| 11 | 96 | |
| 12 | 27 | |
| 13 | 1 | |
| 14 | 45 | |
| 15 | Sequential methotrexate and 5-fluorouracil: Biochemical pharmacology and therapeutic use | 2 |
| 16 | Time and dose relationships for methotrexate (MTX), fluorouracil (FUra) and combinations of these drugs for maximum cell kill in human CCRF-CEM cells | 11 |
| 17 | Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. | 36 |
| 18 | Potent inhibitory activity of trimethoxyquine (tmq), "nonclassical" 2,4, diaminoquinazoline, on mammalian dna synthesis. Abstr. | 11 |
| 19 | Bleomycin, adriamycin, CCNU and oncovin combination (BACO) in advanced and recurrent lymphomas | 1 |
| 20 | Transport of 5-methyltetrahydrofolate by l1210 mouse leukemia cells. Abstr. | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.